Abstract: Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.

Abstract: Provided are a heat dissipation fin construction method, a related apparatus, and a heat dissipation fin. The heat dissipation fin construction method comprises: setting a plurality of structural parameter sets according to the preset numerical ranges of the twill angle, the wave amplitude, and the wavelength of a heat dissipation fin; separately obtaining respective heat transfer coefficients and air side pressure drops of the structural parameter sets, and establishing a fitting relationship between the heat transfer coefficients and the air side pressure drops for structural parameters; generating a corresponding performance map and a corresponding contour map on the basis of performance data of the fitted structural parameter sets; and determining an optimization interval of the wave amplitude and the wavelength of the heat dissipation fin according to the contour map, and constructing the heat dissipation fin according to the optimization interval.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: The present disclosure relates to novel crystalline forms of GFT-505, processes for preparation and uses thereof. The crystalline form CS1, crystalline form CS2, crystalline form CS5 and crystalline form CS6 of GFT-505 provided by the present disclosure have high purity, good stability, low hygroscopicity, good solubility and good mechanical stability. The present disclosure provides a new and better choice for the preparation of drug products containing GFT-505 and is of great significance for drug development.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: The present disclosure relates to novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation and uses thereof. Crystalline form CS1, form CS2 and form CS8 of the present disclosure can be used for preparing drugs treating anemia, which providing new choices for preparing drugs of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid, and having very important value for drug development.

Abstract: The present disclosure relates to novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation and uses thereof. Crystalline form CS1, form CS2 and form CS8 of the present disclosure can be used for preparing drugs treating anemia, which providing new choices for preparing drugs of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid, and having very important value for drug development.

Abstract: The present disclosure relates to two novel crystalline forms of AP26113 and processes for preparation thereof. The crystalline form CS1 and crystalline form CS2 of the present disclosure have advantages in solubility and stability, are suitable for development, and provide a better choice for preparation of pharmaceutical compositions containing AP26113, which is of great significance for drug development.

Abstract: The present disclosure relates to two novel crystalline forms of AP26113 and processes for preparation thereof. The crystalline form CS1 and crystalline form CS2 of the present disclosure have advantages in solubility and stability, are suitable for development, and provide a better choice for preparation of pharmaceutical compositions containing AP26113, which is of great significance for drug development.

Abstract: The present disclosure relates to novel crystalline forms of NBI-98854 (as shown in formula I), preparation process and use thereof. The crystalline forms of NBI-98854 provided by the present disclosure, named as Form CS1 and Form CS2, can be used for preparing drug product treating tardive dyskinesia. The crystalline forms of NBI-98854 provided by the present disclosure have pharmaceutically acceptable solubility and hygroscopicity, good stability and are stable during storage, thereby avoiding changes in drug solubility, dissolution rate, bioavailability and efficacy due to polymorph transformation. This provides a new and better choice for the preparation of drug product containing NBI-98854, which has significant value for future drug development.

Abstract: The present disclosure relates to novel crystalline forms of NBI-98854 (as shown in formula I), preparation process and use thereof. The crystalline forms of NBI-98854 provided by the present disclosure, named as Form CS1 and Form CS2, can be used for preparing drug product treating tardive dyskinesia. The crystalline forms of NBI-98854 provided by the present disclosure have pharmaceutically acceptable solubility and hygroscopicity, good stability and are stable during storage, thereby avoiding changes in drug solubility, dissolution rate, bioavailability and efficacy due to polymorph transformation. This provides a new and better choice for the preparation of drug product containing NBI-98854, which has significant value for future drug development.

Abstract: A logo device for a vehicle is disclosed. The logo device comprises a first shell including a transparent region forming a logo pattern and a nontransparent region and a second shell connected with the first shell. The first shell and the second shell form a sealed cavity therebetween. A bottom plate is disposed in the sealed cavity, and a light guide plate disposed between the bottom plate and the first shell. The light guide plate includes one or more grooves disposed thereon. A circuit board is disposed between the bottom plate and the second shell, including a plurality of illuminating elements thereon. The one or more grooves on the light guide plate receives the plurality of illuminating elements. The light guide plate is configured to direct at least a part of the light generated by the illuminating element toward the transparent region of the first shell.

Abstract: A logo device for a vehicle is disclosed. The logo device comprises a first shell including a transparent region forming a logo pattern and a nontransparent region and a second shell connected with the first shell. The first shell and the second shell form a sealed cavity therebetween. A bottom plate is disposed in the sealed cavity, and a light guide plate disposed between the bottom plate and the first shell. The light guide plate includes one or more grooves disposed thereon. A circuit board is disposed between the bottom plate and the second shell, including a plurality of illuminating elements thereon. The one or more grooves on the light guide plate receives the plurality of illuminating elements. The light guide plate is configured to direct at least a part of the light generated by the illuminating element toward the transparent region of the first shell.